Sort
10,766 grants matching “checkpoint inhibitor”
Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
$446,575Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2023 · CA
Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
$446,575Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2022 · CA
WEE1 inhibition and tumor immunity
$446,500Bin Zhang · Northwestern University At Chicago · R01 · FY2018 · CA
Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBM
$446,457Sangeeta Goswami · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion
$446,389Beth A Weaver · University Of Wisconsin-Madison · R01 · FY2024 · CA
Preventing follicular lymphoma progression and transformation through precision therapy
$446,170Wendy Beguelin · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · CA
The role of transcription elongation defects in immunotherapy resistance in cancers
$446,129Fukun Guo · Cincinnati Childrens Hosp Med Ctr · R01 · FY2019 · CA
The role of transcription elongation defects in immunotherapy resistance in cancers
$446,129Fukun Guo · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · CA
The role of transcription elongation defects in immunotherapy resistance in cancers
$446,129Fukun Guo · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · CA
KRAS inhibitors prime cancer cells for macrophage-mediated destruction
$446,063Kipp A Weiskopf · Whitehead Institute For Biomedical Res · R01 · FY2025 · CA
Targeting ER+ Breast Cancer Through Induced Viral Mimicry
$446,063Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA
KRAS inhibitors prime cancer cells for macrophage-mediated destruction
$446,063Kipp A Weiskopf · Whitehead Institute For Biomedical Res · R01 · FY2023 · CA
Targeting autophagy to enhance immune checkpoint inhibition
$445,954Ravi K Amaravadi · Wistar Institute · P50 · FY2022 · CA
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
$445,923Leaf Huang · Univ Of North Carolina Chapel Hill · U54 · FY2019 · CA
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer
$445,780Bryan R Haugen · University Of Colorado Denver · R01 · FY2023 · CA
Chromosomal Instability as a Therapeutic Target in Anaplastic Thyroid Cancer
$445,778Bryan R Haugen · University Of Colorado Denver · R01 · FY2022 · CA
Immunometabolic pathways enabled by PARP inhibition in breast cancer
$445,716Jennifer L. Guerriero · Brigham And Women'S Hospital · R37 · FY2024 · CA
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer
$445,665Terence Marques Williams · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
$445,626Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$445,383Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$445,383Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
RCAN 1.4 metastasis suppressor in thyroid cancer
$445,344Matthew D Ringel · Ohio State University · R01 · FY2023 · CA
Targeting Metabolic Crosstalk in Pancreatic Cancer
$445,319Christopher J. Halbrook · University Of California-Irvine · R37 · FY2025 · CA
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
$445,226Zhiguo Li · University Of Kentucky · R01 · FY2022 · CA
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
$445,226Zhiguo Li · University Of Kentucky · R01 · FY2025 · CA